Maximizing the adequacy of medication treatment in controlled trials and clinical practice: STAR(*)D measurement-based care
Clicks: 647
ID: 118735
2007
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Popular Article
90.3
/100
647 views
463 readers
Trending
AI Quality Assessment
Not analyzed
Readership in this journal
PopularRanked #1 of 18 articles by views in neuropsychopharmacology : official publication of the american college of neuropsychopharmacology
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
The success of well-developed protocols has been limited in real-world practice, where even effective strategies have not been sufficient to meet patient needs in routine clinical care owing to Axis I and III comorbidities. The Sequenced Treatment Alternatives to Relieve Depression (STAR(*)D) trial …
Abstract Quality Issue:
This abstract appears to be incomplete or contains metadata (44 words).
Try re-searching for a better abstract.
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.